1 / 11

Jumping into the Pool: Is It the Shallow or the Deep End?

Jumping into the Pool: Is It the Shallow or the Deep End?. Anthony D. So, MD, MPA, Quentin Ruiz-Esparza, Eric Giannella , Cecilia Oh, and Pascale Boulet Program on Global Health and Technology Access Sanford School of Public Policy, Duke University, United States ICIUM, Antalya, Turkey

fayola
Download Presentation

Jumping into the Pool: Is It the Shallow or the Deep End?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Jumping into the Pool: Is It the Shallow or the Deep End? Anthony D. So, MD, MPA, Quentin Ruiz-Esparza, Eric Giannella, Cecilia Oh, and PascaleBoulet Program on Global Health and Technology Access Sanford School of Public Policy, Duke University, United States ICIUM, Antalya, Turkey November 16, 2011 Supported in part under NIH/NHGRI grant R01-HG0003763

  2. Malaria Vaccine Initiative: Example of Potential Patent Thicket 167 patent families Shotwell SL. Patent Consolidation and Equitable Access: PATH’s Malaria Vaccines.2007

  3. Pooling Across Value Chain of R&D Proprietary Non-proprietary Exclusive license Non-exclusive license Negotiated access to private compound libraries Public repository of compounds Negotiated access to proprietary data Open access database “Copyleft” rules Open access repositories and journals Traditional subscriber paid-access journal

  4. Tiering Arrangements for Pools Paying market Resource-limited market

  5. Tiering by Disease Neglected diseases based on FDA Priority Voucher list Neglected diseases defined by WHO Trachoma Buruli Ulcer Fascioliasis Trypanosomiasis Schistosomiasis Rabies TB Dracunculiasis Cysticercosis Malaria Onchocerciasis Echinococcosis Cholera Soil-transmitted helminthiasis Chagas Lymphatic Filariasis Leishmaniasis Leprosy Dengue WIPO Consortium’s Re:Search Yaws Pool for Open Innovation Against Neglected Tropical Diseases

  6. Tiering by Country Income Status *World Health Organization. Department of Measurement and Health Information. December 2004. †UN Conference on Trade and Development. The Least Developed Countries Report. 2009.

  7. Status of GSK pool patents in LDCs Source: GlaxoSmithKline, 2009.

  8. Tiering Access to AIDS Drugs Extent of coverage for different tiering criteria For AIDS treatment Levels of coverage under different tiering schemes The 15.2 Million Person Gap • Access under Bristol-Myers Squibb Category 1 tiering arrangement: 11.0 million • Access under Gilead Category 1 tiering arrangement: 26.2 million • Access under Merck Category 1 tiering arrangement: 23.1 million • Access under Abbott Category 1 tiering arrangement: 22.4 million • Access under the Gilead-MPP Agreement for TDF: 26.4 million Data Source: UNAIDS

  9. The “Shift” of Disease Burden from Low- to Middle-Income Countries Global distribution of NTD burden* by 2002country income classification** Global distribution of NTD burden* by 2009 country income classification** *World Health Organization. Department of Measurement and Health Information. December 2004. **World Bank. World Bank national accounts data, and OECD National Accounts data files. 2010.

  10. Evolving Patent Pooling for Neglected Diseases GSK-proposed Patent Pool Traditional Patent Pool Research Commons Trusted, Third Party Intermediary

  11. A Pool for Neglected Diseases POOL PULL PUSH OPEN SOURCE

More Related